Arbella Therapeutics and Polymed Biopharmaceuticals announce exclusive collaboration agreement to develop and commercialize novel oncology therapies in Greater China and South Korea

On May 15, 2021 Arbella Therapeutics, a U.S. early stage biotechnology company focused on the discovery and development of innovative small molecule therapies, and Hangzhou Polymed Biopharmaceuticals ("Polymed"), a leading biopharmaceutical company in China, reported a collaboration to develop and commercialize ARB-085 – a preclinical development candidate targeting dual EGFR and HER2 Exon 20 mutations – in Greater China and South Korea (Press release, Polymed Biopharmaceuticals, MAY 15, 2021, View Source [SID1234630620]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the collaboration, Arbella is eligible to receive an upfront collaboration fee and additional payments contingent on certain development and regulatory milestones, plus royalties on net product sales. Polymed will lead the development and commercialization of ARB-085 in Greater China.

"We are glad to have begun this partnership with Polymed to progress ARB-085 in China, where there is a significant unmet medical need for the treatment of non-small cell lung cancer caused by genetic mutations. We look forward to working in close collaboration with Polymed to continue the development of ARB-085 as we progress toward the clinical stage," said Fred Martin, Ph.D., Founder and Manager of Arbella.

"We look forward to a successful collaboration with Arbella for developing ARB-085," said Dr. Jason Shaoyun Xiang, the founder and CEO of Polymed. "In addition to pushing forward highly innovative internal PROTAC projects, Polymed is leveraging its capabilities for collaboration with leading world-class institutions to bring urgently-needed therapeutics into clinical development", said Dr. Xiang.

Discovered through research conducted in collaboration with the Dana-Farber Cancer Institute ("DFCI") of Harvard University, ARB-085 is a potent and selective dual EGFR/HER2 Exon 20 insertion inhibitor for non-small cell lung cancers, currently in preclinical stage.